SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 25.66+2.8%Jan 30 9:30 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Edward Paule who wrote (11257)8/16/1999 11:01:00 PM
From: aknahow  Read Replies (2) of 17367
 
Ed, your post made me think you were trying to prove there could be no bad news since XOMA which already has experienced a lawsuit knows that it must release bad news, and of course that it must not hype. XOMA did not tell shareholders the drug failed. They said they believed it was clinically effective.

"<<<<<<<< If Xoma "knows" now and doesn't "tell" until October, and Xoma tanks as a result, then everyone
who buys between tomorrow and October could very well be members of a class action lawsuit.>>>>>>>>"
wammy.

Obvious that XOMA does not know its' drug is not effective. Nor can those that sell
now thinking it was not
effective prevail in any subsequent lawsuit. XOMA will be able to prove it said that it
believed the drug was
effective. <g>

No there is nothing or no page that says nothing can be said until the FDA lets one
say it. But given the nature
of the approval process it is probably wiser to avoid automatic law suits which could
follow when a regulatory
agency does something perverse. One avoids a double whammy. So, even though I
would like to have hard data
and think they should release the number of deaths in each arm I can see why a
conservative management
would not.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext